Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04322968 · ClinicalTrials.gov registry record · Phase 3

Ketamine Infusion for Comorbid PTSD and Chronic Pain

A Phase 3 study, sponsored by VA Ann Arbor Healthcare System.

Completed
Registry status
Phase 3
Development phase
41
Enrollment target

NCT04322968: Completed Phase 3 study, sponsored by VA Ann Arbor Healthcare System.

NCT04322968 is a Phase 3 study that has completed, run by VA Ann Arbor Healthcare System. The registered enrollment target is 41 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04322968, a Phase 3 study, has completed, sponsored by VA Ann Arbor Healthcare System.

COMPLETED
Registry status
Phase 3
Development phase
41 participants
Enrollment target

Study Summary

The purpose of the study is to investigate the effectiveness of low dose IV ketamine infusion in the treatment of patients with PTSD and comorbid chronic pain. Hypothesis: A single ketamine infusion should be associated with significantly greater reduction in core PTSD symptom levels after the treatment and such an effect is not only due to its analgesic properties but also through unknown mechanism of action that maybe related to NMDA/AMPA receptor modulation.

Primary Outcome

Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms

Interventions

  • DRUG A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2018-01-09
Est. Completion 2019-06-04
Phase Phase 3
VA Ann Arbor Healthcare System

5 total trials

What the finished NCT04322968 record still lists

NCT04322968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms. is the first listed.

NCT04322968 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04322968 about?

NCT04322968 is a clinical study titled "Ketamine Infusion for Comorbid PTSD and Chronic Pain". The purpose of the study is to investigate the effectiveness of low dose IV ketamine infusion in the treatment of patients with PTSD and comorbid chronic pain. Hypothesis: A single ketamine infusion should be associated with significantly greater reduction in core PTSD symptom levels after the trea...

What is the current status of trial NCT04322968?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2018-01-09. Estimated completion is 2019-06-04.

What interventions are being tested in trial NCT04322968?

The interventions under investigation include: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms. (DRUG).

Who is sponsoring clinical trial NCT04322968?

This trial is sponsored by VA Ann Arbor Healthcare System, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04322968's enrollment target sits among peer trials

41 1877th of 2000 higher than 123 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03449238 · 41 participants · Phase 1

    Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

  • NCT03900793 · 41 participants · Phase 1

    Losartan + Sunitinib in Treatment of Osteosarcoma

  • NCT04082520 · 41 participants · Phase 2

    Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

  • NCT04220190 · 41 participants · Phase 2

    RAPA-501 Therapy for ALS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04322968, the US trial registry maintained by the National Library of Medicine. NCT04322968 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.